
Clinical TrialAug 6, 2026, 08:05 AM
Theriva Biologics Doses First Patient in VIRAGE2 Phase 2a Trial
AI Summary
Theriva Biologics announced the dosing of the first patient in its VIRAGE2 Phase 2a clinical trial for VCN-01 in first-line metastatic pancreatic ductal adenocarcinoma (PDAC). This small proof-of-concept study aims to evaluate more frequent repeated dosing of VCN-01 to refine the regimen for a potential future pivotal Phase 3 trial. Enrollment is expected to conclude in H2 2026, with initial data anticipated by Q3 2027, building on positive observations from the VIRAGE Phase 2b trial and regulatory feedback.
Key Highlights
- First patient dosed in VIRAGE2 Phase 2a clinical trial for VCN-01 in metastatic PDAC.
- VIRAGE2 evaluates more frequent repeated dosing of VCN-01 with standard-of-care chemotherapy.
- Enrollment for VIRAGE2 trial is expected to be completed in H2 2026.
- Initial pharmacodynamic and safety/tolerability data are anticipated by Q3 2027.
- The study is a small proof-of-concept trial involving 6 evaluable patients.
- VIRAGE2 builds on positive VIRAGE Phase 2b data and feedback from EMA and FDA.
- VCN-01 has been administered to 143 patients across various clinical trials.
Price Impact
More from TOVX